- Policy
- Incentive-paid items for generic substitution fell to 12,757
- by Lee, Hye-Kyung Aug 11, 2021 05:58am
- 12,757 items were found to be eligible for incentives of 30% of the difference in drug prices if pharmacies dispense generic substitution, which is cheaper than prescription drugs. It decreased 48 items compared to the previous month. The HIRA recently guided the 'Billing Method of Drugs Subjected to Incentives for low-price generic substitu
- Company
- Reimbursement for Kymriah will be deliberated by CDRC
- by Eo, Yun-Ho Aug 10, 2021 05:54am
- The discussions on listing the ultra-high-priced, one-shot treatment ‘Kymriah’ for health insurance benefits will begin. According to industry sources, Novartis Korea’s first-in-class CAR-T (chimeric antigen receptor-T) treatment will be put as an agenda for deliberation in September at Health Insurance Review and Assessment Service’s
- Policy
- Pfizer is working hard to introduce Prevenar-20 in Korea
- by Lee, Tak-Sun Aug 10, 2021 05:54am
- Pfizer, which supplies Prevenar-13, pneumococcal vaccine that ranks overwhelmingly at the top of the domestic market, is also working hard to introduce the next-generation vaccine. It started clinical trials for East Asians to introduce Prevenar-20, which was approved by the U.S. Food and Drug Administration (FDA) in June. Prevenar-20 h
- Company
- Marken establishs a cGMP cold-chain center in Korea
- by Nho, Byung Chul Aug 10, 2021 05:54am
- A cGMP compliant cold-chain center for the distribution of pharmaceuticals that will soon be complete in Korea is receiving attention. According to industry sources, the global biopharmaceutical·clinical trial logistics company Marken and its parent company UPS have worked together to establish a 1,000-pyeong cold chain storage and distr
- Policy
- Supply of Oseltamivir has declined 55% since COVID outbreak
- by Lee, Hye-Kyung Aug 10, 2021 05:54am
- After COVID-19 epidemic, the supply of respiratory medicine has dropped by nearly half. According to the HIRA's "Medicine Distribution Newsletter No. 1" published on the 5th, the supply of respiratory drugs in spring and winter since 2020 decreased by 40.6% compared to the same period last year, and the supply of Oseltamivir used to treat flu
- Policy
- Vaccination agencies are expected to work too hard in Oct
- by Lee, Tak-Sun Aug 10, 2021 05:54am
- Confusion is expected in October, when COVID vaccinations and flu vaccinations overlap, due to a significant increase in the work of inoculation institutions. In October, the largest number of people are scheduled to receive the second round of COVID vaccinations, and vaccinations to prevent seasonal flu will also begin in earnest. Front-l
- Opinion
- [FOCUS] Why retrieve the insurance paid for CA?
- by Chon, Seung-Hyun Aug 9, 2021 06:04am
- The tug-of-war between the health authorities and pharmaceutical companies over the negotiation on the restitution of insurance claims paid for the brain function enhancer choline alfoscerate (cholinergic agents) has been now ongoing for 8 months. In December of last year, the Ministry of Health and Welfare (MOHW) ordered the National Hea
- Policy
- It will be reviewed by the Regulatory Reform Committee
- by Lee, Jeong-Hwan Aug 9, 2021 06:02am
- Whether or not to introduce the "no change in manufacturing" policy of consignment generic, which is being opposed by the domestic pharmaceutical industry, will eventually be decided based on the results of the Regulatory Reform Committee review. The MFDS finished collecting opinions on the related industries by March this year after announc
- Company
- Antengen Korea's blood cancer treatment Xpovio is approved
- by Eo, Yun-Ho Aug 9, 2021 06:02am
- The Chinese pharmaceutical company Antengene’s blood cancer drug ‘Xpovio’ has entered the domestic market. According to industry sources, Antengene Korea’s first-in-class XPO1 inhibitor Xpovio (Selinexor) was approved by the Ministry of Food and Drug Safety (MFDS) on the 29th of last month. The drug had been previously designated an O
- Policy
- Benefits for Imotun, Tagen-F and Legalon have been deleted
- by Lee, Hye-Kyung Aug 9, 2021 06:01am
- As it was classified as a health functional food in major foreign countries, it was decided to delete the benefit of four already registered medicines. However, Hanlim's Entelon, (Vitis vinifera) can be reimbursed only for lymph edema supplementary therapy due to breast cancer treatment. The remaining two indications, blood circulation, retin
